Does Bank Going Public Affect the Borrowers' ESG Performance? Evidence From a Quasi‐Natural Experiment in China
Accounting & Finance · 2026-06 · 66 (2) · 1232-1252
DOI: 10.1111/acfi.70209 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounting & Finance, online erschienen am 16.03.2026. Verfasst von Hao Huang und 2 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Using a quasi‐natural experiment of commercial bank initial public offerings (IPOs), this study examines how bank listings affect borrowing firms' environmental, social, and governance (ESG) performance. The results reveal significant improvements in borrowers' ESG performance, particularly in the environmental and social dimensions, after lending banks go public. The positive effect is stronger for private enterprises, firms in highly marketized regions, and borrowers of city or rural commercial banks. The impact of national joint‐stock commercial bank listings is comparatively weaker. Mechanism analyses reveal that bank IPOs enhance lenders' bargaining power and strengthen ESG disclosure requirements, driving improvements in borrowers' ESG outcomes.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, H., Tang, L., & Zhao, L. (2026). Does Bank Going Public Affect the Borrowers' ESG Performance? Evidence From a Quasi‐Natural Experiment in China. Accounting & Finance, 66(2), 1232-1252. https://doi.org/10.1111/acfi.70209
Vancouver
Huang H, Tang L, Zhao L. Does Bank Going Public Affect the Borrowers' ESG Performance? Evidence From a Quasi‐Natural Experiment in China. Accounting & Finance. 2026;66(2):1232-1252. doi:10.1111/acfi.70209
BibTeX
@article{Huang2026,
author = {Huang, Hao and Tang, Li and Zhao, Ling},
title = {Does Bank Going Public Affect the Borrowers' ESG Performance? Evidence From a Quasi‐Natural Experiment in China},
journal = {Accounting & Finance},
year = {2026},
volume = {66},
number = {2},
pages = {1232--1252},
doi = {10.1111/acfi.70209}
}
EUVIMED